Hans-Jurgen Stellbrink
Overview
Explore the profile of Hans-Jurgen Stellbrink including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
93
Citations
3965
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Stephan C, Spinner C, Rieke A, Christensen S, Mauss S, Schreiber S, et al.
HIV Med
. 2024 Oct;
26(2):239-251.
PMID: 39476488
Background: Tenofovir alafenamide (TAF) was introduced in the European Union in 2015 as a novel prodrug of tenofovir showing similar efficacy in clinical trials and a more favorable safety profile...
2.
Gonzalez-Cordon A, Assoumou L, Moyle G, Waters L, Johnson M, Domingo P, et al.
J Antimicrob Chemother
. 2023 Aug;
78(9):2361-2365.
PMID: 37539492
Background: In the NEAT022 trial, switching from boosted PIs (PI/r) to dolutegravir in people with HIV (PWH) with high cardiovascular risk decreased plasma lipids, soluble CD14 and adiponectin, and showed...
3.
Sempere A, Assoumou L, Gonzalez-Cordon A, Waters L, Rusconi S, Domingo P, et al.
Clin Infect Dis
. 2023 May;
77(7):991-1009.
PMID: 37207617
Background: Integrase inhibitors have been recently linked to a higher risk for hypertension. In NEAT022 randomized trial, virologically suppressed persons with human immunodeficiency virus (HIV, PWH) with high cardiovascular risk...
4.
Sax P, Arribas J, Orkin C, Lazzarin A, Pozniak A, DeJesus E, et al.
EClinicalMedicine
. 2023 May;
59:101991.
PMID: 37200995
Background: Bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) is a single-tablet regimen recommended for HIV-1 treatment. The safety and efficacy of B/F/TAF as initial therapy was established in two Phase 3 studies: 1489 (vs...
5.
Maasoumy B, Ingiliz P, Spinner C, Cordes C, Stellbrink H, Schulze Zur Wiesch J, et al.
JHEP Rep
. 2023 Feb;
5(3):100650.
PMID: 36852107
Background & Aims: EASL guidelines recommend 8 weeks of treatment with sofosbuvir plus velpatasvir (SOF/VEL) for the treatment of acute or recently acquired HCV infection, but only 6- and 12-week...
6.
Waters L, Assoumou L, Gonzalez-Cordon A, Rusconi S, Domingo P, Gompels M, et al.
Clin Infect Dis
. 2022 Oct;
76(5):861-870.
PMID: 36259527
Background: In the NEAT022 trial, virologically suppressed persons with human immunodeficiency virus (HIV) at high cardiovascular risk switching from protease inhibitors to dolutegravir either immediately (DTG-I) or after 48 weeks...
7.
Segal-Maurer S, DeJesus E, Stellbrink H, Castagna A, Richmond G, Sinclair G, et al.
N Engl J Med
. 2022 May;
386(19):1793-1803.
PMID: 35544387
Background: Patients with multidrug-resistant human immunodeficiency virus type 1 (HIV-1) infection have limited treatment options. Lenacapavir is a first-in-class capsid inhibitor that showed substantial antiviral activity in a phase 1b...
8.
Kolbe K, Wittner M, Hartjen P, Hufner A, Degen O, Ackermann C, et al.
Front Immunol
. 2022 May;
13:867167.
PMID: 35529864
Background: γδ T cells are unconventional T cells that have been demonstrated to be crucial for the pathogenesis and potentially for the cure of HIV-1 infection. The ectonucleotidase CD39 is...
9.
Monin M, Kummerle T, Schneider J, Cordes C, Heiken H, Stellbrink H, et al.
HIV Res Clin Pract
. 2022 Mar;
23(1):15-21.
PMID: 35234092
Switching from a three-drug regimen (3DR: boosted darunavir [bDRV] and two nucleoside reverse transcriptase inhibitors [NRTIs]) to a two-drug regimen (2DR: bDRV and dolutegravir [DTG]) demonstrated non-inferiority with regard to...
10.
Amele S, Karachalia Sandri A, Rodger A, Vandekerckhove L, Benfield T, Milinkovic A, et al.
HIV Med
. 2021 Dec;
23(6):684-692.
PMID: 34882940
Objectives: Although direct-acting antivirals (DAAs) can clear HCV in nearly all HIV/HCV-coinfected individuals, high rates of reinfection may hamper efforts to eliminate HCV in this population. We investigated reinfection after...